keyword
MENU ▼
Read by QxMD icon Read
search

Disease-modifying antirheumatic drugs

keyword
https://www.readbyqxmd.com/read/28527160/study-of-bone-mineral-density-bmd-in-patients-with-rheumatoid-arthritis-and-its-co-relation-with-severity-of-the-disease
#1
Liyakat Ali Gauri, Qadir Fatima, Sharanbasu Diggi, Asim Khan, Ambreen Liyakat, B R Ajay
INTRODUCTION: Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown etiology marked by a symmetric, peripheral polyarthritis.1-3 People with rheumatoid arthritis are at increased risk of osteoporosis. Hence this article intends to highlight the importance of BMD measurement in patients with RA as a tool for assessment of disease activity and severity. OBJECTIVE: To evaluate Bone Mineral Density in patients of Rheumatoid Arthritis and Co-relate it with severity of disease...
April 2017: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/28526972/patient-experiences-attitudes-and-expectations-towards-receiving-information-about-anti-tnf-medication-a-quantitative-study
#2
Jon Packham, Paul Arkell, Tom Sheeran, Ann Brownfield, Anthony Cadwgan, Sarah Ryan
The objective of the study was to measure patient attitudes and experience of information received during drug counselling for rheumatoid arthritis (RA) medications. This is a cross-sectional UK postal questionnaire study. Three RA patient groups-disease-modifying antirheumatic drugs (DMARDs) only, first anti-tumour necrosis factor (anti-TNF) and failed anti-TNF-were sent postal questionnaires. Data on patient history/demographics, drug counselling experience, knowledge of drug side effects, attitudes to vaccinations, cancer screening and blood borne virus testing was collected; 264/679 (39%) patients responded (median age 65 years, 66% female, median disease duration 15 years)...
May 19, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28521841/tnf-inhibitors-appear-to-inhibit-disease-progression-and-improve-outcome-in-takayasu-arteritis-an-observational-population-based-time-trend-study
#3
Birgir Gudbrandsson, Øyvind Molberg, Øyvind Palm
BACKGROUND: Magnetic resonance imaging (MRI) and computed tomography (CT) angiography have now largely replaced interventional angiography in the diagnoses and follow up of Takayasu arteritis (TAK) but data on the effects of this change of imaging method on diagnostic delay and vascular damage, and detailed data on the effect of different treatment regimens on the accumulation of vascular damage are missing. The aim of this study was to assess time trends in diagnostic delay, therapeutic approaches, arterial lesion accrual, persistent disease activity and remission rates in TAK...
May 18, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28508282/malignancy-incidence-management-and-prevention-in-patients-with-rheumatoid-arthritis
#4
REVIEW
Katelynn M Wilton, Eric L Matteson
Traditional and biologic disease-modifying antirheumatic drugs (DMARDs) are effective medications for the management of rheumatoid arthritis (RA). However, the effects of these medications on immune function raises concern that they may increase long-term cancer risk. The baseline risk for some cancers appears to differ in patients with RA compared to the general population, with the former having an increased risk of lymphoma, lung cancer and renal cancer, but a decreased risk of colorectal and breast cancer...
May 15, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28505163/anti-citrullinated-peptide-antibodies-are-the-strongest-predictor-of-clinically-relevant-radiographic-progression-in-rheumatoid-arthritis-patients-achieving-remission-or-low-disease-activity-a-post-hoc-analysis-of-a-nationwide-cohort-in-japan
#5
Tomohiro Koga, Akitomo Okada, Takaaki Fukuda, Toshihiko Hidaka, Tomonori Ishii, Yukitaka Ueki, Takao Kodera, Munetoshi Nakashima, Yuichi Takahashi, Seiyo Honda, Yoshiro Horai, Ryu Watanabe, Hiroshi Okuno, Toshiyuki Aramaki, Tomomasa Izumiyama, Osamu Takai, Taiichiro Miyashita, Shuntaro Sato, Shin-Ya Kawashiri, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Tomoki Origuchi, Hideki Nakamura, Kiyoshi Aoyagi, Katsumi Eguchi, Atsushi Kawakami
OBJECTIVES: To determine prognostic factors of clinically relevant radiographic progression (CRRP) in patients with rheumatoid arthritis (RA) achieving remission or low disease activity (LDA) in clinical practice. METHODS: Using data from a nationwide, multicenter, prospective study in Japan, we evaluated 198 biological disease-modifying antirheumatic drug (bDMARD)-naïve RA patients who were in remission or had LDA at study entry after being treated with conventional synthetic DMARDs (csDMARDs)...
2017: PloS One
https://www.readbyqxmd.com/read/28496328/association-between-use-of-disease-modifying-antirheumatic-drugs-and-diabetes-in-patients-with-ankylosing-spondylitis-rheumatoid-arthritis-or-psoriasis-psoriatic-arthritis-a-nationwide-population-based-cohort-study-of-84-989-patients
#6
Hsin-Hua Chen, Der-Yuan Chen, Chi-Chen Lin, Yi-Ming Chen, Kuo-Lung Lai, Ching-Heng Lin
PURPOSE: The aim of this study is to investigate the association between the use of disease-modifying antirheumatic drugs (DMARDs) and diabetes mellitus (DM) in patients with ankylosing spondylitis (AS), rheumatoid arthritis (RA), or psoriasis/psoriatic arthritis (PS/PSA). PATIENTS AND METHODS: This retrospective cohort study used a nationwide, population-based administrative database to enroll 84,989 cases with AS, RA, or PS/PSA who initiated treatment with anti-tumor necrosis factor (anti-TNF) drugs or nonbiologic DMARDs...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28495399/evaluation-of-toll-like-receptor-gene-family-variants-as-prognostic-biomarkers-in-rheumatoid-arthritis
#7
Silvia Torices, Lorena Alvarez-Rodríguez, Ignacio Varela, Pedro Muñoz, Alejandro Balsa, M López-Hoyos, Víctor Martinez-Taboada, Jose L Fernández-Luna
Rheumatoid arthritis (RA) is a systemic autoimmune disease whose main feature is persistent joint inflammation. Toll-like receptors (TLRs) play critical roles in the activation of innate and adaptive immune responses, and influence the activity of NFκB, a key player in chronic inflammation. We aimed at investigating the association of TLR allelic variants with susceptibility and severity of RA through a systematic, high-throughput, analysis of TLR genes. All coding exons and flanking regions of nine members of the TLR family (TLR1-9) were analyzed in 66 patients with RA and 30 healthy controls by next generation sequencing...
May 7, 2017: Immunology Letters
https://www.readbyqxmd.com/read/28474138/effects-of-iguratimod-on-the-levels-of-circulating-regulators-of-bone-remodeling-and-bone-remodeling-markers-in-patients-with-rheumatoid-arthritis
#8
Xuetong Wang, Cuili Ma, Ping Li, Feng Zhao, Liqi Bi
This study aims to investigate the effect of iguratimod, a novel disease-modifying antirheumatic drug, alone or combined with methotrexate (MTX), on the serum levels of regulators of bone remodeling (receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), and Dickkopf-1 (DKK-1)) and bone remodeling markers (C-telopeptide of type I collagen (CTX-I) and procollagen type I N-terminal propeptide (PINP)) in patients with rheumatoid arthritis (RA). Patients with RA were treated with iguratimod, MTX, or their combination for 12 months...
May 4, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28465768/comparing-healthcare-costs-associated-with-oral-and-subcutaneous-methotrexate-or-biologic-therapy-for-rheumatoid-arthritis-in-the-united-states
#9
Joseph Lee, Ryan Pelkey, Julieanna Gubitosa, Michael F Henrick, Michael L Ganz
BACKGROUND: Methotrexate (MTX) is the primary disease-modifying antirheumatic drug used for the treatment of rheumatoid arthritis (RA). Optimizing the use of oral and subcutaneous MTX may delay the use of expensive biologic therapies; the effect of such a delay on overall medical costs is currently unknown. OBJECTIVE: To compare the 5-year healthcare costs of treatment pathways for patients with RA who initiate oral MTX in the United States. METHODS: We identified patients with RA in the Symphony Health Solutions database (Integrated Dataverse) who initiated treatment with oral MTX in 2009 and had RA-related claims for each year through 2014...
February 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28465766/biologic-disease-modifying-antirheumatic-drugs-in-a-national-privately-insured-population-utilization-expenditures-and-price-trends
#10
Christopher B Atzinger, Jeff J Guo
BACKGROUND: Spending on biologic drugs is a significant driver of drug expenditures for payers in private health plans. Biologic disease-modifying antirheumatic drugs (DMARDs) are some of the most effective and costly treatments in a physician's arsenal. Understanding the total annual expenditure, the average cost per prescription, and the impact of cost-sharing is important for drug benefit managers. OBJECTIVE: To assess drug utilization, expenditures, out-of-pocket (OOP) cost, and price trends of biologic DMARDs in patients with rheumatoid arthritis (RA) in a large managed care organization...
February 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28465764/sociodemographic-determinants-of-out-of-pocket-expenditures-for-patients-using-prescription-drugs-for-rheumatoid-arthritis
#11
Kumar Mukherjee, Khalid M Kamal
BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory disease that has a substantial economic impact on patients. Patients with RA are at an increased risk for disability and for loss of income. The inclusion of biologic drugs in RA therapy has increased the cost of treatment. Little is known about the relationship between sociodemographic characteristics and the out-of-pocket (OOP) expenditures for prescription drugs for patients with RA, including biologics, disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and analgesics...
February 2017: American Health & Drug Benefits
https://www.readbyqxmd.com/read/28464909/multicenter-inception-cohort-of-enthesitis-related-arthritis-variation-in-disease-characteristics-and-treatment-approaches
#12
Sabrina Gmuca, Rui Xiao, Timothy G Brandon, Ilaria Pagnini, Tracey B Wright, Timothy Beukelman, Esi M Morgan, Pamela F Weiss
BACKGROUND: Enthesitis-related arthritis (ERA) is a specific subtype of juvenile idiopathic arthritis (JIA) defined according to the International League of Associations for Rheumatology (ILAR) criteria. We aimed to characterize the clinical features and treatment regimens in an inception cohort of children with ERA. METHODS: We performed a retrospective, cross-sectional, multicenter cohort study including subjects diagnosed with ERA between 1989 and 2012. Patients all fulfilled the ILAR criteria for ERA within 3 months of initial presentation to the rheumatology clinic...
May 2, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28461647/utility-of-power-doppler-ultrasound-detected-synovitis-for-the-prediction-of-short-term-flare-in-psoriatic-patients-with-arthritis-in-clinical-remission
#13
Santiago Ruta, Josefina Marin, Maria Laura Acosta Felquer, Leandro Ferreyra-Garrot, Javier Rosa, Ricardo García-Monaco, Enrique R Soriano
OBJECTIVE: Power Doppler ultrasound (PDUS) has been shown to detect subclinical synovitis in psoriatic arthritis (PsA), but its value is not yet fully understood. The aim of this study was to evaluate PDUS features at joint level in patients with PsA in clinical remission and to investigate its value for predicting short-term flares. METHODS: Consecutive patients with PsA in clinical remission according to the attending rheumatologist and who fulfill minimal disease activity criteria and/or 28-joint Disease Activity Score in remission criteria underwent PDUS examination of 18 joints...
May 1, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28450312/long-term-outcome-is-better-when-a-methotrexate-based-treatment-strategy-is-combined-with-10-mg-prednisone-daily-follow-up-after-the-second-computer-assisted-management-in-early-rheumatoid-arthritis-trial
#14
Mary Safy, Jwg Jacobs, N D IJff, Jwj Bijlsma, J M van Laar, Mjh deHair
OBJECTIVES: In the second Computer-Assisted Management in Early Rheumatoid Arthritis trial, patients had started with methotrexate and 10 mg prednisone (MTX+pred) or placebo (MTX+plac). After the trial, prednisone was tapered and stopped, if possible. The objective was to compare, during the post-trial follow-up between the two former strategy groups, initiation of the first biological disease-modifying antirheumatic drug (bDMARD), radiographic outcome and onset of glucocorticoid (GC)-related comorbidities...
April 27, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28448195/design-characteristics-of-the-corrona-japan-rheumatoid-arthritis-registry
#15
Hisashi Yamanaka, Mitsumasa Kishimoto, Dimitrios A Pappas, Jeffrey D Greenberg, Joel M Kremer, Yoshiya Tanaka
OBJECTIVES: The primary objective is to prospectively study the comparative safety and effectiveness of older and newer classes of nonbiologic DMARDs (Disease-modifying antirheumatic drugs), biologic DMARDs and targeted synthetic therapies approved for rheumatoid arthritis (RA) in a real-world patient population in Japan. METHODS: Prospective, multicenter, noninterventional, observational study across geographic distribution of both private and public institutions for patients with RA who are newly prescribed one of the following medications: (1) methotrexate; (2) anti-TNF biologic DMARDs; (3) non-TNF biologic DMARDs; and (4) approved JAK inhibitors at the time of enrollment into the registry...
April 27, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28447156/-success-for-a-new-generation-of-disease-modifying-antirheumatic-drugs-the-janus-kinase-inhibitor-baricitinib-in-rheumatoid-arthritis
#16
REVIEW
G Keyßer
No abstract text is available yet for this article.
April 26, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28439423/rheumatoid-arthritis-what-do-mri-and-ultrasound-show
#17
EDITORIAL
Iwona Sudoł-Szopińska, Lennart Jans, James Teh
Rheumatoid arthritis is the most common inflammatory arthritis, affecting approximately 1% of the world's population. Its pathogenesis has not been completely understood. However, there is evidence that the disease may involve synovial joints, subchondral bone marrow as well as intra- and extraarticular fat tissue, and may lead to progressive joint destruction and disability. Over the last two decades, significant improvement in its prognosis has been achieved owing to new strategies for disease management, the emergence of new biologic therapies and better utilization of conventional disease-modifying antirheumatic drugs...
March 2017: Journal of Ultrasonography
https://www.readbyqxmd.com/read/28429118/-how-frequent-are-poor-prognostic-markers-in-rheumatoid-arthritis-an-estimate-based-on-three-epidemiologic-cohorts
#18
K Albrecht, A Richter, Y Meissner, D Huscher, L Baganz, K Thiele, M Schneider, A Strangfeld, A Zink
BACKGROUND: Unfavorable prognostic factors-high disease activity, early erosions, and autoantibodies-should be considered when making treatment decisions in rheumatoid arthritis (RA). There are little data on the frequency of individual poor prognostic factors among RA patients in daily care. METHODS: Disease activity (Disease Activity Score, DAS28), erosions, antibodies against citrullinated peptides or rheumatoid factor (ACPA/RF+), previous treatment failure, inflammation markers, and functional disability (FFbH < 70) were defined as prognostic factors...
April 20, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28422773/infections-in-rheumatoid-arthritis
#19
Fabiola Atzeni, Ignazio Francesco Masala, Manuela di Franco, Piercarlo Sarzi-Puttini
PURPOSE OF REVIEW: The purpose of this review is to provide an update concerning recent advances in the evidence- based study of serious infections in patients with rheumatoid arthritis (RA) treated with biological drugs or conventional disease-modifying antirheumatic drugs (DMARDs), concentrating on studies published in the last 18 months. RECENT FINDINGS: New studies have further strengthened existing evidence relating the use of biological drugs to serious infections...
April 18, 2017: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/28420837/clinical-characteristics-of-rheumatoid-arthritis-patients-achieving-functional-remission-with-six-months-of-biological-dmards-treatment
#20
Yusuke Miwa, Ryo Takahashi, Yuzo Ikari, Airi Maeoka, Shinichiro Nishimi, Nao Oguro, Tomoki Hayashi, Mika Hatano, Sakiko Isojima, Ryo Yanai, Tsuyoshi Kasama, Yoichi Toyoshima, Katsunori Inagaki, Kenji Sanada
Objective Although previous studies have reported the prognostic factors for functional remission, no reports have cited the predictive factors. Our aim was to study the predictive factors for functional remission, which is a treatment goal in rheumatoid arthritis (RA), after receiving biological disease-modifying antirheumatic drugs (bDMARDs) treatment for six months. Methods The study consisted of 333 RA patients treated with bDMARDs for six months. The following patient characteristics were investigated: age, gender, disease duration, type of bDMARDs, baseline steroid and methotrexate dosage, and levels of serum rheumatoid factor, matrix metalloprotease, anti-cyclic citrullinated peptides antibody, tumor necrosis factor-α, and interleukin-6...
2017: Internal Medicine
keyword
keyword
116670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"